A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma
Mingzhen Zhou, Sihui Zhu, Chen Xu, Baorui Liu, Jie Shen
Topics & Concepts
MedicineHepatocellular carcinomaClinical endpointAdverse effectInternal medicineImmunotherapyPhases of clinical researchOncologyGastroenterologyAntibodyClinical trialCancerImmunologyFibroblast Growth Factor ResearchPeptidase Inhibition and AnalysisHepatocellular Carcinoma Treatment and Prognosis